TMS Therapy · Hayward, CA
Patients who come asking about TMS for anxiety usually fall into one of three groups. The first has depression with significant anxiety symptoms — diagnostically called anxious depression — and they want to know whether TMS will help both. The second has generalized anxiety disorder, panic disorder, or social anxiety as a primary diagnosis and they have tried multiple medications without enough relief. The third has PTSD and they have read encouraging things about TMS in trauma circles. The honest answer is different for each.
The short version: TMS has strong evidence for anxious depression, growing evidence for OCD (where it’s FDA-cleared with the Deep TMS H1 coil), preliminary evidence for PTSD, and limited evidence for primary generalized anxiety disorder. Off-label use is increasingly common in TMS practices, but it should come with a clear-eyed conversation about what we know and what we don’t.[1]
TMS has strong evidence for anxious depression. Growing evidence for OCD. Mixed evidence for primary GAD and PTSD.
What TMS is FDA-cleared for
The FDA clearances matter because they determine what insurance will cover, what protocols are standardized, and where the strongest evidence base sits.
Major depressive disorder — FDA-cleared since 2008 for standard 10-Hz rTMS, with iTBS and Deep TMS additions in subsequent years. This is the largest evidence base and the path through which most patients enter TMS.[1]
Obsessive-compulsive disorder (OCD) — Deep TMS with the H1 coil (BrainsWay) received FDA clearance for OCD in 2018. The H7 coil received OCD clearance shortly after. Standard figure-8 coil TMS does not have OCD clearance.[2]
Anxious depression — Standard rTMS protocols are cleared as part of the broader MDD indication; anxious depression is not a separate FDA category but the indication includes patients with significant anxiety symptoms.[2]
Smoking cessation — Deep TMS H4 coil, 2020.
Notably absent: generalized anxiety disorder, panic disorder, social anxiety disorder, and PTSD all remain off-label uses. Treatment is legal and clinically reasonable in many cases, but coverage and standardization are weaker.
TMS for anxious depression (strong evidence)
Roughly two-thirds of patients with major depressive disorder also meet criteria for clinically significant anxiety symptoms, and the European evidence-based guidelines from Lefaucheur and colleagues assign Level A evidence (definite efficacy) to high-frequency left-DLPFC rTMS for depression — a population that includes anxious depression specifically.[2]
Across multiple analyses of patients enrolled in depression trials, those with high baseline anxiety scores typically respond to TMS at rates comparable to (or in some studies slightly better than) those with lower anxiety. Anxiety symptoms tend to improve alongside mood symptoms, often on a similar timeline. For patients whose primary complaint is “depression with terrible anxiety” — which is most patients I see — TMS is a reasonable next step after two failed antidepressant trials.
TMS for OCD (FDA-cleared)
OCD got FDA clearance for Deep TMS in 2018 based on a multicenter RCT that demonstrated significantly greater YBOCS reductions with active stimulation versus sham. The standardized protocol targets the medial prefrontal cortex and anterior cingulate cortex with the H7 coil, delivered 5 days per week for 6 weeks.[3]
Response rates in real-world OCD-TMS practice cluster around 40-45% — somewhat lower than depression-TMS but meaningful for a condition where pharmacological response rates can be similarly modest. For patients with OCD who have not responded to SSRIs at high doses and CBT with exposure and response prevention, Deep TMS is now a credible next step.
Where the off-label conversation gets careful
Primary GAD, panic, and PTSD — limited but evolving evidence.
For generalized anxiety disorder and panic disorder, the published evidence base is small — mostly open-label case series and a handful of randomized trials with mixed results. The Lefaucheur guidelines assign Level B (probable efficacy) to high-frequency right-DLPFC rTMS for PTSD, based on a moderate-quality literature.[2] A 2024 Cochrane systematic review of 13 RCTs in 577 PTSD patients concluded that active rTMS “probably makes little to no difference” to PTSD severity immediately following treatment, with significant heterogeneity across studies and clear evidence of efficacy not yet established.[4] Off-label use can still be justified for patients who have exhausted standard options, but the conversation should include the honest evidence picture.
What “off-label” actually means in practice
Off-label means the FDA has not specifically cleared a device or protocol for a particular condition — it does not mean the use is illegal or experimental in the harmful sense. Many evidence-based psychiatric treatments are used off-label routinely (lithium for unipolar augmentation, bupropion for ADHD, gabapentin for anxiety, etc.).
For TMS specifically, off-label use most commonly looks like:
Standard 10-Hz left-DLPFC protocol for primary GAD or panic disorder. The protocol is identical to depression treatment; the underlying logic is that the same prefrontal-limbic circuits implicated in depressed mood are involved in chronic worry and panic. Response data is limited.
Right-DLPFC low-frequency rTMS for PTSD. Based on the Lefaucheur Level B evidence. Standardized protocols exist but are not as well-validated as the depression protocols.
Deep TMS H1 coil for anxious depression. The H1 coil is FDA-cleared for MDD, and many practices use it for patients whose depression has significant anxiety features.
Coverage: most commercial insurance plans will not cover off-label TMS. Patients pay out of pocket or use HSA/FSA funds. Be specific with your TMS clinic about cost before committing.
How clinicians decide whether to offer TMS for anxiety
In my Hayward office, the conversation goes like this. First, what is the primary diagnosis. If it’s MDD with anxious features, TMS is on the table after two failed antidepressants — same as any depression patient. If it’s primary GAD or panic, I want to see what’s been tried first: at minimum two SSRIs/SNRIs at adequate dose and duration, plus a course of CBT, before considering off-label TMS. If it’s OCD, Deep TMS with the H7 coil is appropriate after one or two SSRI trials at high dose plus ERP.
Second, what is the patient’s tolerance for ambiguity. Off-label use means I can’t promise the response rates I can quote for FDA-cleared indications. Patients who want a high-confidence intervention should usually exhaust the better-evidenced options first. Patients who have exhausted those options and want to try something with reasonable mechanistic rationale may benefit.
Third, what does the practical picture look like — insurance, schedule, willingness to commit to 4-6 weeks of daily sessions. Off-label TMS that you can’t complete is worse than not starting.
What’s cleared, what’s off-label, what the evidence actually says.
| Condition | Status | Evidence |
|---|---|---|
| Major depressive disorder | FDA-cleared | Strong — Level A evidence, 2008+ clearance, established protocols[2] |
| Anxious depression | FDA-cleared (MDD) | Strong — anxiety symptoms improve alongside mood on similar timeline |
| OCD | FDA-cleared (Deep TMS H7) | Strong — 2018 clearance, 40-45% response rates[3] |
| PTSD | Off-label | Mixed — Level B per Lefaucheur, 2024 Cochrane review found “little to no difference” vs sham[4] |
| Generalized anxiety disorder | Off-label | Limited — small open-label series, few RCTs |
| Panic disorder | Off-label | Limited — small case series only |
Questions to ask if your clinic is offering TMS for anxiety
What is the specific indication you’re treating? MDD with anxious features, primary GAD, panic disorder, OCD with H7 coil, or PTSD? Each has a different evidence base and a different protocol.
Is this FDA-cleared for this indication, or off-label? The honest answer matters for both expectations and insurance.
What protocol will you use? 10-Hz left DLPFC, low-frequency right DLPFC, Deep TMS H7 for OCD, etc. Match this against published literature for your condition.
What is the expected response rate based on published data? Be wary of overpromising. For FDA-cleared depression: 40-55% response, 25-35% remission. For OCD with Deep TMS: similar range. For primary GAD: response data is limited; honest answer is “we don’t have good numbers yet.”
How will you measure outcomes? For depression: PHQ-9 or MADRS. For OCD: YBOCS. For GAD: GAD-7. For PTSD: PCL-5. Tracking the right scale matters.
What is the cost if insurance doesn’t cover it? Out-of-pocket TMS courses typically run $8,000-$15,000. Some clinics offer cash-pay rates that are significantly lower than the chargemaster.
What to ask if your clinic offers TMS for anxiety.
- What is the specific indication? Anxious depression vs primary GAD vs OCD vs PTSD — different evidence bases.
- Is this FDA-cleared or off-label? Honest answer matters for expectations and insurance.
- Which protocol? 10-Hz left DLPFC, low-freq right DLPFC, Deep TMS H7 — match to published literature.
- What response rate do you cite? Beware of overpromising. Honest off-label answer: “limited data.”
- What scale will you use? PHQ-9, YBOCS, GAD-7, PCL-5 — track the right one.
- Cost if insurance doesn’t cover? Out-of-pocket TMS courses run $8,000–$15,000 typically.
The bottom line
TMS has clear, FDA-cleared utility for major depressive disorder, including patients with significant anxiety features. It has FDA clearance for OCD through the Deep TMS H7 coil. It has growing but mixed off-label evidence for PTSD, GAD, and panic disorder, with the strongest off-label case being for PTSD using Lefaucheur Level B-supported right-DLPFC low-frequency protocols.[2][4]
If anxiety is part of your depression, TMS is a reasonable next step after failed antidepressants. If anxiety is your primary diagnosis and you’ve exhausted standard treatments, off-label TMS may be worth a careful conversation — with a clinic that is honest about the evidence, transparent about cost, and committed to measuring whether it’s working.
If you’re in Hayward or the East Bay considering TMS for anxiety, depression with anxious features, or OCD, that conversation is what a consultation is for.
Evidence-based decisions about FDA-cleared and off-label options.
Exxceed Wellness is a psychiatric practice in Hayward, CA. We’re transparent about which TMS indications have strong evidence, which are off-label, what the real-world response rates look like, and what your out-of-pocket cost will be if your insurance won’t cover.
Founder, Exxceed Wellness · Hayward, CA · Telehealth across California
References
- McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):16cs10905. PMID: 28541649. doi:10.4088/JCP.16cs10905.
- Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol. 2020;131(2):474-528. PMID: 31901449. doi:10.1016/j.clinph.2019.11.002.
- Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021;132(1):269-306. PMID: 33243615. doi:10.1016/j.clinph.2020.10.003.
- Brown R, Cherian K, Jones K, et al. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. Cochrane Database Syst Rev. 2024;8(8):CD015040. PMID: 39092744. doi:10.1002/14651858.CD015040.pub2.
- Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019;364:l1079. PMID: 30917990. doi:10.1136/bmj.l1079.
- Zis P, Shafique F, Hadjivassiliou M, et al. Safety, tolerability, and nocebo phenomena during transcranial magnetic stimulation: a systematic review and meta-analysis of placebo-controlled clinical trials. Neuromodulation. 2020;23(3):291-300. PMID: 30896060. doi:10.1111/ner.12946.
Comments are closed